[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
January 2010

A Novel Mutation in the TAP2 Gene in Bare Lymphocyte Syndrome: Association With Metastatic Cutaneous Squamous Cell Carcinoma

Arch Dermatol. 2010;146(1):96-98. doi:10.1001/archdermatol.2009.354

Bare lymphocyte syndrome (BLS) is a rare disease characterized by a severe reduction in the cell surface expression of HLA molecules (HLA class I, type I BLS; HLA class II, type II BLS). Patients with BLS-I present with bronchiectasias and skin ulcers associated with granulomatous inflammation.1,2 Synthesis of HLA class I molecules includes transportation of cytoplasmic peptides into the endoplasmic reticulum by the transporter-associated antigen-processing (TAP) heterodimers (TAP1 and TAP2). Peptide-loaded HLA class I molecules may interact with cytotoxic CD8+ T cells, natural killer (NK) cells, and γδ T cells.3 Patients with BLS-I, who have a defective TAP complex, may have 1 of 4 different mutations. Tissue typing and molecular analysis of 15 patients demonstrated that they were homozygous for a defective TAP1 or TAP2 mutation.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×